Department of Bioengineering and Nano-Bioengineering, Incheon National University Incheon 22012, Republic of Korea.
Division of Bioengineering, Incheon National University Incheon 22012, Republic of Korea.
Theranostics. 2024 Sep 3;14(14):5643-5661. doi: 10.7150/thno.97139. eCollection 2024.
Inflammatory bowel disease (IBD) is a chronic disorder characterized by persistent inflammation of the gastrointestinal tract. Due to the elusive causes and complex mechanisms of this disorder, the development of highly effective therapeutic drugs is crucial. Extracellular vesicles (EVs) are small membrane-bound structures released by cells into the surrounding environment. Recent research has witnessed a substantial surge in the utilization of plant-derived EVs that offer advantages such as high productivity, low production costs, diverse biological functions, and low cytotoxicity. Herein, Red cabbage-derived EVs (Rabex) were investigated and engineered as potential therapeutic agents for IBD. Rabex was engineered by surface conjugation with hyaluronic acid (t-Rabex) to simultaneously enhance the targeting of intestinal epithelial and immune cells, thereby improving their therapeutic targeting and efficacy. The properties and therapeutic potential of t-Rabex were assessed through both studies and experiments, focusing on their capacity to reach the gastrointestinal tract and exert a therapeutic effect compared to unmodified Rabex. Rabex exhibited dual functions, including the suppression of inflammation in macrophages and promotion of colon epithelial cell regeneration, both of which are critical for effective IBD treatment. and studies of t-Rabex have demonstrated its superior targeting efficiency to the gastrointestinal tract and therapeutic efficacy compared to Rabex, making it a promising and more effective IBD treatment. Understanding the mechanism of action of t-Rabex in colonic tissues highlighted its anti-inflammatory, antioxidative, and tight-junction maintenance properties. These findings underscore the potential of t-Rabex as a precise therapeutic agent for IBD and shed light on the diverse applications of plant-derived EVs.
炎症性肠病（IBD）是一种慢性疾病，其特征为胃肠道持续炎症。由于这种疾病的病因难以捉摸，机制复杂，因此开发高效的治疗药物至关重要。细胞外囊泡（EVs）是细胞释放到周围环境中的小型膜结合结构。最近的研究大量利用植物源性 EVs，这些 EVs 具有高生产力、低成本、多样的生物学功能和低细胞毒性等优点。在此，研究了源自红甘蓝的 EVs（Rabex），并将其工程化为 IBD 的潜在治疗剂。Rabex 通过与透明质酸（t-Rabex）表面缀合进行工程化，以同时增强对肠上皮细胞和免疫细胞的靶向作用，从而提高其治疗靶向性和疗效。通过研究和实验评估了 t-Rabex 的特性和治疗潜力，重点研究了其到达胃肠道并发挥治疗作用的能力，与未修饰的 Rabex 相比。Rabex 表现出双重功能，包括抑制巨噬细胞中的炎症和促进结肠上皮细胞再生，这两者对于有效的 IBD 治疗都至关重要。与 Rabex 相比，t-Rabex 的研究和实验表明其对胃肠道的靶向效率更高，治疗效果更好，使其成为一种有前途且更有效的 IBD 治疗方法。对 t-Rabex 在结肠组织中的作用机制的研究强调了其抗炎、抗氧化和维持紧密连接的特性。这些发现突显了 t-Rabex 作为 IBD 精确治疗剂的潜力，并展示了植物源性 EVs 的多种应用。
